AbbVie poised to take out Allergan for more than $60B

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

The WSJ reports that AbbVie (NYSE:ABBV) is in the final stages of a $188/share bid for Allergan (NYSE:AGN) in a transaction valued at more than $60B.

ABBV is down 5% premarket while AGN is up 30%.

Update: AbbVie has confirmed its bid of $188.24 per share in cash and stock, valuing the deal at ~$63B. Specifically, it will offer $120.30 in cash plus 0.8660 of an ABBV share for each AGN share.

Subscribe for full text news in your inbox